Concordat Bio · Pharma BD & M&A

The always-on BD and M&A desk, run by AI agents.

Mid-sized pharma cannot justify a ten-person BD desk — and cannot afford to miss the next in-license or tuck-in. Concordat Bio runs the scouting, scoring, drafting, modeling, and integration planning those deals depend on, every day, for every therapeutic gap on your watchlist.

Request a pilotSee the workflow
Tenant-isolated SaaS · deal flow and IP stay separate per customer

The mid-market gap

Big-Pharma-grade pipeline pressure.
Lean headcount.

Specialty and mid-sized pharma face the same pipeline-replenishment pressure as the largest players. Every in-license, every tuck-in acquisition matters. The BD team is two or three people, and the manual scouting, evaluation, and paperwork for a single opportunity consumes weeks of analyst time.

Databases such as DrugPatentWatch, DealForma, and ITONICS stop short at signal without action. The category is being validated by Insilico Medicine’s Automated Partnering System, but Insilico is itself a licensor — its priorities are its own pipeline. Concordat Bio is purpose-built for the buy-side mid-market.

Platform

Three jobs the BD desk does and yours does not have the headcount for.

Concordat Bio is not a database and not a chatbot. It is a working desk — agents that run the recurring work, in parallel, with the audit trail your CFO and counsel will expect.

01

Scout, continuously.

Agents monitor biotech pipelines across indications and modalities. New INDs, financings, presentations, and clinical readouts are scored against your portfolio gaps as they ship.

02

Draft, defensibly.

Term sheets, acquisition financial models, and IC memos are produced with sourced inputs. Counsel reviews the language; Concordat supplies the logic and the numbers.

03

Integrate, with memory.

Playbooks are grounded in post-merger experience, not generic templates. Concordat accounts for the scientific, clinical, commercial, and cultural stitching that BD leaders consistently underweight.

Workflow

From target list to letter-of-intent, in days rather than months.

  1. 01

    Sense

    Continuous pipeline sensing

    Agents watch biotech pipelines across indication, modality, and stage. They pick up new INDs, financings, partnership announcements, and trial readouts as they ship — not as a quarterly refresh.

  2. 02

    Score

    Targets ranked against your portfolio

    Each candidate is scored against the therapeutic-portfolio gaps you set. Concordat shows you the gaps before it shows you the targets, so the ranking is defensible at IC.

  3. 03

    Draft

    Term sheets, drafting-side support

    Where you want it, the platform produces a term-sheet outline and rationale grounded in comparable transactions. Counsel is for the language; Concordat is for the logic.

  4. 04

    Model

    Acquisition financial model, day one

    For tuck-in and platform deals, an integration-ready financial model is produced in parallel with diligence — sourcing assumptions from public filings and disclosed comparables, with all inputs auditable.

  5. 05

    Integrate

    Playbooks drawn from post-merger experience

    Integration playbooks reflect a decade of real separation-and-integration work, not generic templates. They account for scientific, clinical, commercial, and cultural stitching — the dimensions BD leaders consistently underweight.

Engagement modes

Pick the depth that fits the deal.

Concordat can run the full pipeline end-to-end or sit alongside your existing BD team on a single high-priority candidate. Most customers start with one in-license and expand.

Identify, score, and draft terms for a single in-licensing candidate.

Agents scan public pipelines, publications, and presentations against your portfolio gaps; produce a one-pager, term-sheet outline, and integration-options memo.

Cadence
5–8 business days

Typical deliverables

  • Portfolio-gap memo
  • Target dossier (5–15 pages)
  • Term-sheet outline

What ships

Coverage, scoring, drafting, models, and integration — without the analyst hours.

01 — CoverageBiotech pipelines worldwideCompany filings, INDs, conference abstracts, trial registries, KOL commentary
02 — ScoringMatched to your portfolio gapsYou define the gaps; the platform ranks against them, with rationale per candidate
03 — Deal docsTerm sheets, financial models, IC memosOutputs you can hand to counsel and finance without rewriting the first draft
04 — ConfidentialityTenant-isolated workspace per customerPer-customer deal flow stays separate. No cross-tenant leakage, no shared embeddings
05 — IntegrationPipelines into your CRM, finance, IPConnects to internal pipeline, IP, and clinical-trial systems on day one

Provenance

Built by someone who has lived the integration.

Concordat Bio is led from Basel by a Novartis executive who served as Global Financial Analyst for Pharma Development and as Head of Global Integration & Separation. More than a decade of business-development licensing and M&A integration leadership informs every workflow on the platform.

  • Scouting. Indicators informed by the same diligence grids used in real licensing transactions.
  • Modeling. Financial assumptions sourced from public filings and disclosed comparables, not guessed.
  • Integration. Playbooks account for separation timelines, day-one readiness, and the cultural stitch that breaks more integrations than it should.

Get started

Start with one target. Expand when the platform proves itself.

Pilots run on a single high-priority candidate for one customer-defined portfolio gap. The platform produces real deliverables — a target dossier, a term-sheet outline, a financial model, and an integration playbook — under your NDA, in your tenant.

Request a pilotconcordat-bio@polsia.app

Direct line

concordat-bio@polsia.app
HeadquartersBasel, CH
DeploymentTenant-isolated SaaS
Pilot formatSingle-target, NDA-scoped